HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesAltretamine
Chemical structure of CAS 645-05-6

Altretamine

In Stock•Starting at $15 for 100 mg•Purity ≥ 97%
CAS No.645-05-6
MDL No.MFCD00549245
MFC9H18N6
MW210.28
InChI KeyUUVWYPNAQBNQJQ-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
100 mg97%$15In Stock
250 mg97%$23In Stock
1 g97%$60In Stock
5 g97%$130In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Altretamine may cause developmental and male reproductive toxicity as per state or federal government labeling requirements.

CAS No.645-05-6
Product NameAltretamine

Associated Conditions

neoplasm·lymphoma·sarcoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Solvent, emulsifier and drug concentration factors in poly(D,L-lactic acid) microspheres containing hexamethylmelamine.

Journal of microencapsulation • Vol. 19, Issue 1 • 2002
PMID: 11811763DOI: 10.1080/02652040110081398

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.

British journal of cancer • Vol. 86, Issue 8 • 2002
PMID: 11953879PMC: PMC2375343DOI: 10.1038/sj.bjc.6600258

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

Gynecologic oncology • Vol. 81, Issue 1 • 2001
PMID: 11277650DOI: 10.1006/gyno.2000.6089

Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.

Japanese journal of clinical oncology • Vol. 31, Issue 2 • 2001
PMID: 11302345DOI: 10.1093/jjco/hye012

Documentation

Similar Products